DYADIC INTERNATIONAL, INC.

CORPORATE FACT SHEET, APRIL 2021

Fast Facts

Nasdaq: DYAI

Market Cap:	$134.7 M[1]
Cash & equivalents:	$29.2 M[2]
Shares Outstanding:	~27.5 M[2]
Debt & Warrants:	None
Insider Ownership:	~30%
2020 R&D Revenue:	$1.6 M

[1] as of 04/23/2021
[2] as of 12/31/2020

Management Team

Mark Emalfarb
Founder, Chief Executive Officer

Ping Rawson
Chief Financial Officer

Ronen Tchelet
VP of Research and Business Development

Matthew Jones
Managing Director, Business Development and Licensing

Contact

Corporate Headquarters

Dyadic International, Inc.

140 Intracoastal Pointe Dr. Ste. 404

Jupiter, FL 33477-5094

Phone: 561-743-8333

Fax: 561-743-8343

Email: info@dyadic.com

www.dyadic.com

Investment Highlights

Next-Gen Protein Expression Biotech with Top-tier Global Partners

Proprietary & patented C1-cell protein production platform

- Designed to bring biologic vaccines and drugs to market faster, in greater quantities, at lower cost at flexible commercial scales

Competitive advantages

- Robust scientific data demonstrating high productivity, stability, and purity for a growing number of therapeutic and vaccine relevant protein classes

Opportunistic business development

- Emphasis on large and growing addressable human and animal health markets, many shots on goal including vaccines and antibodies for infectious diseases and therapeutic proteins for diabetes, oncology, and arthritis

Global strategic partnerships

- Well-established, global biological R&D organizations, top-tier animal and human health pharmaceutical companies, as well as governmental and private agencies

Experienced management

- Highly experienced and energized management team and world-class Board of Directors & Advisors

Proprietary Technology

C1 is a hyper-productive gene expression platform technology with key competitive advantages over existing technologies

Safe

- C1 received a generally recognized as safe (GRAS) certification from the US FDA in 2009

Higher Yields

- Potential to produce greater quantities of vaccines & drugs using C1 in less timeframe as compared to CHO & baculovirus cells

Faster Production

- C1 produces vaccines & drugs significantly faster (12–14 days) than CHO cells (41–54 days)

Lower Cost

- Flexible production scale; C1 media <1/20 of the cost of CHO media; no viral or endotoxin removal required

DYADIC INTERNATIONAL, INC.

CORPORATE FACT SHEET, APRIL 2021

Return-focused Business Development in Biopharma Markets

Advancing C1 platform via internal programs & external collaborations that fund Dyadic's R&D initiatives

Animal Health Collaborations

- Established 3 new and 1 expanded fully funded collaborations with leading animal health companies in 2020; Dyadic has entered into agreements with all of the top 4 animal health companies
- In partnership with ZAPI, Dyadic has developed antigens for both the Schallmenberg and Rift Valley Fever viruses; C1 was selected as designated antigen expression platform for the ZAPI program after demonstrating far greater antigen productivity than baculovirus cells
- Expanded partnership with ZAPI in Q1 2021 for additional animal studies using the SBV and RVFV antigens produced from C1

Human Health Collaborations (non-COVID)

- 5 new and 3 expanded fully funded collaborations in 2020 with top-tier global pharma companies and small biotech companies to express therapeutics of commercial interest
- Fully funded collaboration with Jiangsu Hengrui Medicine Co., Ltd., the largest pharma company in China (by market cap), for the development of selected biologic drugs
- Entered a feasibility study with the University of Oslo for a potential influenza vaccine
- Entered potential new market with fully funded collaboration with TurtleTree Scientific in 2021 to develop a number of recombinant protein growth factors

Ongoing Dyadic C1 SARS-CoV-2 Vaccine & mAb Programs



Global COVID-19 Initiatives

- C1 produced SARS-CoV-2-S RBD antigen has been evaluated in 10 animal trials by academic, industrial, and governmental R&D groups globally
- Advancing DYAI-100 vaccine candidate, a C1 produced SARS-CoV-2-S-RBD antigen, towards a **first-in-human Phase 1 clinical trial that is expected to launch by H2 2021**; CR2O and Parexcel will support preclinical and clinical development of DYAI-100
- Developing additional proprietary and third-party monovalent and multivalent COVID-19 variant vaccine candidates
- Expanded partnership with South Korea's Medytox Inc. to co-develop C1 enabled COVID-19 variant vaccines and/or boosters

Dyadic Forward-Looking Statements

Certain statements contained in this Corporate Fact Sheet are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in Dyadic's most recent filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this presentation, which are based on information available to us on the date hereof. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com